Novartis has terminated its August 2025 option and license agreement with BioArctic, forfeiting up to $772 million in potential milestone payments tied to the BrainTransporter blood-brain barrier delivery platform. BioArctic retains the $30 million upfront payment and states the decision concerns the undisclosed Novartis antibody program rather than the delivery technology, with collaborations involving Eli Lilly, Eisai and Bristol Myers Squibb continuing. The platform exploits transferrin receptor transport to raise antibody brain exposure up to 70-fold in preclinical models, but remains untested in humans.
Key Points
- Novartis ends BioArctic deal worth up to $802 million
- BrainTransporter uses transferrin receptor; 70-fold brain exposure preclinically
- Four other partnerships continue; platform not yet in humans
Longevity Analysis
Fewer than 1% of circulating antibodies cross into brain tissue, which makes delivery, not drug design, the rate-limiting constraint on nearly every neurodegeneration therapeutic in development. Hijacking the transferrin receptor — the same route the brain uses to acquire iron — turns an existing transport channel into a therapeutic corridor, a strategy that depends on respecting rather than overriding the barrier's selective filtering. Commercial withdrawal from a single program says little about the biology; it does underscore that the practical ceiling on protecting cognitive function over decades still sits at the interface between blood and brain.
Original published by Longevity.Technology, by Kyle Umipig.